Xintela AB
1XT
Company Profile
Business description
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
Contact
Medicon Village
Lund22381
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.90 | 7.20 | 0.08% |
| CAC 40 | 8,072.10 | 95.63 | -1.17% |
| DAX 40 | 23,907.17 | 298.19 | -1.23% |
| Dow JONES (US) | 48,097.84 | 403.43 | -0.83% |
| FTSE 100 | 10,460.77 | 23.36 | -0.22% |
| HKSE | 25,321.34 | 446.74 | -1.73% |
| NASDAQ | 22,736.63 | 70.86 | -0.31% |
| Nikkei 225 | 55,278.06 | 1,000.99 | -1.78% |
| NZX 50 Index | 13,617.89 | 2.32 | -0.02% |
| S&P 500 | 6,828.79 | 40.71 | -0.59% |
| S&P/ASX 200 | 8,940.30 | 3.30 | 0.04% |
| SSE Composite Index | 4,108.57 | 26.09 | 0.64% |